Intellia's CRISPR-Engineered Cell Therapy Receives FDA Orphan Drug Tag For Bone Marrow Cancer

Intellia Therapeutics Inc's NTLA CRISPR-powered T cell therapy has received an FDA orphan drug designation.

  • The autologous T cell receptor therapy, dubbed NTLA-5001, is being evaluated in a Phase 1/2a trial in acute myeloid leukemia, the white blood cell cancer that affects blood and bone marrow.
  • A week ago, the company dosed the first patient in the NTLA-5001 Phase 1/2a trial in AML after receiving standard first-line therapy. The trial will enroll 54 patients.
  • Read Next: Intellia Shares Updated Data On Gene Editing Durability In Rare Disease.
  • With the orphan drug status, Intellia snags the potential for tax credits on clinical testing, plus fee exemptions and a seven-year marketing exclusivity should NTLA-5001 secure an FDA green light.
  • Related content: Benzinga's Full FDA Calendar
  • The designation is granted to therapeutics that aim to treat diseases impacting 200,000 or fewer people in the U.S.
  • Price Action: NTLA shares closed 1.64% higher at $67.07 during after-hours trading on Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareFDAGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!